ESDR

Mary Kay Inc. & European Society for Dermatological Research Partner to Award Educational Research Grants Advancing Skin Health/Skin Disease

Retrieved on: 
Wednesday, May 17, 2023

Mary Kay Inc. , a global leader in skin care innovation, in partnership with the European Society for Dermatological Research , recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May.

Key Points: 
  • Mary Kay Inc. , a global leader in skin care innovation, in partnership with the European Society for Dermatological Research , recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May.
  • View the full release here: https://www.businesswire.com/news/home/20230517005040/en/
    Mary Kay partnered with European Society for Dermatological Research (ESDR) to award inaugural Mary Kay-ESDR Skin Health/Skin Disease Research Grants.
  • Congratulations to our 2022 recipients, Dr. Clarisse Ganier and Dr. Michael Cangkrama, who will each receive $20,000 grants to further their contributions in skin disease research.
  • (Photo: Mary Kay Inc.)
    “Mary Kay is dedicated to advancing skin and nutritional health research globally, and we know this cannot be done alone.

HydraForce Launches Innercept™ Digital Proportional Control

Retrieved on: 
Monday, March 13, 2023

HydraForce , a leading manufacturer of hydraulic valves and manifolds, has launched its Innercept™ Digital Proportional Control with Linear Variable Differential Transformer (LVDT), which offers plug-and-play simplicity with servovalve accuracy.

Key Points: 
  • HydraForce , a leading manufacturer of hydraulic valves and manifolds, has launched its Innercept™ Digital Proportional Control with Linear Variable Differential Transformer (LVDT), which offers plug-and-play simplicity with servovalve accuracy.
  • When attached to a solenoid-operated proportional valve, it improves the accuracy, repeatability and response of the proportional valve.
  • Innercept can be easily adapted for a variety of applications where precision and response are key.”
    The new digital proportional control integrates an LVDT position sensor with a coil-mounted valve driver that provides closed-loop control.
  • To learn more about HydraForce’s new Innercept Digital Proportional Control with integrated LVDT, visit hydraforce.com/innercept .

Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 1, 2022

Aileron plans to report initial data from the breast cancer trial in 4Q 2022, an interim readout in 2Q 2023, and topline results in 3Q 2023.

Key Points: 
  • Aileron plans to report initial data from the breast cancer trial in 4Q 2022, an interim readout in 2Q 2023, and topline results in 3Q 2023.
  • Presented detailed results from Phase 1 study in healthy volunteers at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics.
  • Net Loss: Net loss for the quarter ended September 30, 2022, was $6.4 million, compared to $6.7 million for the corresponding quarter in 2021.
  • The basic and diluted net loss per share for the third quarter of 2022 was $0.07 compared to $0.07 for the third quarter of 2021.

ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, October 28, 2022

Cash used in operating activities for the third quarter of 2022 was US$9.1 million compared to US$7.6 million in the same period in 2021.

Key Points: 
  • Cash used in operating activities for the third quarter of 2022 was US$9.1 million compared to US$7.6 million in the same period in 2021.
  • Research and development expenses were US$8.0 million in the third quarter of 2022 compared to US$5.3 million in the third quarter of 2021.
  • General and administrative expenses were US$2.3 million in the third quarter of 2022 compared to US$2.8 million in the third quarter of 2021.
  • Net loss attributable to stockholders for the third quarter of 2022 was US$10.9 million compared to a net loss of US$8.6 million for the third quarter of 2021.

Mary Kay Announces Skin Health Grants and Delivers Eye-Opening Research on the Biology of Droopy Eyes at the 51st Annual European Society for Dermatological Research Meeting

Retrieved on: 
Tuesday, October 25, 2022

(Credit: Mary Kay Inc.)

Key Points: 
  • (Credit: Mary Kay Inc.)
    Mary Kay will be awarding two $20,000 grants to researchers conducting groundbreaking and innovative studies in skin health or skin diseases, for which eligible applicants can apply through December 9, 2022.
  • With these funds, Mary Kay hopes to empower researchers to uncover new perspectives and interventional strategies in dermatology.
  • Mary Kay presented exciting new findings at the 51st annual ESDR meeting as part of its ongoing research focused on the biology of skin aging.
  • The annual European Society for Dermatological Research (ESDR) Conference is held in Europe each year every September.

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

Retrieved on: 
Friday, September 30, 2022

It is yet another burden layered on top of their already-daunting fight against cancer, said Dr. Paus.

Key Points: 
  • It is yet another burden layered on top of their already-daunting fight against cancer, said Dr. Paus.
  • Ailerons vision is to bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy.
  • We look forward to our anticipated data readouts from that trial later this year and into 2023.
  • Aileron previously conducted in vitro studies showing that ALRN-6924 protected human fibroblasts in cell culture from multiple chemotherapies, but not p53-mutant breast cancer cells.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting

Retrieved on: 
Wednesday, September 28, 2022

The new translational data presented at ESDR provide novel and differentiated mechanistic insights into IL-13R1 mediated cytokine signaling in AD.

Key Points: 
  • The new translational data presented at ESDR provide novel and differentiated mechanistic insights into IL-13R1 mediated cytokine signaling in AD.
  • These data support the importance of IL-13R1 as a target in AD, providing a potentially differentiated approach for eblasakimab to reduce inflammation and itch in AD patients.
  • Data presented in this poster confirm prior results of eblasakimab dampening neuronal sensitization caused by IL-4 and IL-13 on human neurons.
  • 001- 38475), including the Companys Annual Report on Form 20-F filed with the US Securities and Exchange Commission on March 25, 2022.

ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting

Retrieved on: 
Tuesday, September 13, 2022

The posters will be available to view online in the Investor Relations section of ASLANs website following presentation: https://ir.aslanpharma.com/ .

Key Points: 
  • The posters will be available to view online in the Investor Relations section of ASLANs website following presentation: https://ir.aslanpharma.com/ .
  • In September 2021, ASLAN announced positive results from the Phase 1b multiple-ascending-dose study that established proof-of-concept of ASLAN004 and supported its potential as a novel treatment for AD.
  • In January 2022, ASLAN initiated the TREK-AD Phase 2b trial to evaluate the safety and efficacy of eblasakimab in moderate-to-severe AD patients.
  • ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

Retrieved on: 
Thursday, June 9, 2022

COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.

Key Points: 
  • COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.
  • "Lars Iversen brings substantial experience and an extensive international network in the field of dermatology to the company," said Jesper J. Lange, CEO of MC2 Therapeutics.
  • Professor Lars Iversen has been a member of the International Psoriasis Council (IPC) board of directors since 2017.
  • Lars Iversen (Professor, MD, DMSc) is chair professor in dermatology at University of Aarhus since 2012.

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

Retrieved on: 
Thursday, June 9, 2022

COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.

Key Points: 
  • COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.
  • "Lars Iversen brings substantial experience and an extensive international network in the field of dermatology to the company," said Jesper J. Lange, CEO of MC2 Therapeutics.
  • Professor Lars Iversen has been a member of the International Psoriasis Council (IPC) board of directors since 2017.
  • Lars Iversen (Professor, MD, DMSc) is chair professor in dermatology at University of Aarhus since 2012.